S'abonner

Mechanisms of IFN-γ–induced apoptosis of human skin keratinocytes in patients with atopic dermatitis - 28/04/12

Doi : 10.1016/j.jaci.2012.02.020 
Ana Rebane, PhD a, b, , Maya Zimmermann, PhD a, , Alar Aab, MSc a, Hansjörg Baurecht, MSc c, Andrea Koreck, MD d, Maire Karelson, MD e, Kristi Abram, MD e, Tauno Metsalu, MSc f, Maire Pihlap, BSc b, Norbert Meyer, MD a, Regina Fölster-Holst, MD c, Nikoletta Nagy, MD, PhD d, g, Lajos Kemeny, MD d, g, Külli Kingo, MD, PhD e, h, Jaak Vilo, PhD f, Thomas Illig, MD i, j, Mübeccel Akdis, MD, PhD a, Andre Franke, PhD k, Natalija Novak, MD l, Stephan Weidinger, MD c, Cezmi A. Akdis, MD a
a Swiss Institute of Allergy and Asthma Research (SIAF), University of Zürich, Davos, Switzerland 
b Molecular Pathology, Faculty of Medicine, University of Tartu, Tartu, Estonia 
c Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany 
d Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary 
e Department of Dermatology, Tartu University Hospital, Tartu, Estonia 
f Institute of Computer Science, University of Tartu, Tartu, Estonia 
g Dermatological Research Group of the Hungarian Academy of Sciences, Szeged, Hungary 
h Department of Physiology, Centre of Molecular and Clinical Medicine, University of Tartu, Tartu, Estonia 
i Institute of Epidemiology, Helmholtz Zentrum Munich, Munich, Germany 
j Hannover Unified Biobank, Hannover Medical School, Hannover, Germany 
k Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel, Kiel, Germany 
l Department of Dermatology and Allergy, University of Bonn, Bonn, Germany 

Corresponding author: Ana Rebane, PhD, Swiss Institute of Allergy and Asthma Research (SIAF), Obere Strasse 22, 7270 Davos, Switzerland.

Abstract

Background

Enhanced apoptosis of keratinocytes is the main cause of eczema and spongiosis in patients with the common inflammatory skin disease atopic dermatitis (AD).

Objective

The aim of the study was to investigate molecular mechanisms of AD-related apoptosis of keratinocytes.

Methods

Primary keratinocytes isolated from patients with AD and healthy donors were used to study apoptosis by using annexin V/7-aminoactinomycin D staining. Illumina mRNA Expression BeadChips, quantitative RT-PCR, and immunofluorescence were used to study gene expression. In silico analysis of candidate genes was performed on genome-wide single nucleotide polymorphism data.

Results

We demonstrate that keratinocytes of patients with AD exhibit increased IFN-γ–induced apoptosis compared with keratinocytes from healthy subjects. Further mRNA expression analyses revealed differential expression of apoptosis-related genes in AD keratinocytes and skin and the upregulation of immune system–related genes in skin biopsy specimens of chronic AD lesions. Three apoptosis-related genes (NOD2, DUSP1, and ADM) and 8 genes overexpressed in AD skin lesions (CCDC109B, CCL5, CCL8, IFI35, LYN, RAB31, IFITM1, and IFITM2) were induced by IFN-γ in primary keratinocytes. The protein expression of IFITM1, CCL5, and CCL8 was verified in AD skin. In line with the functional studies and AD-related mRNA expression changes, in silico analysis of genome-wide single nucleotide polymorphism data revealed evidence of an association between AD and genetic markers close to or within the IFITM cluster or RAB31, DUSP1, and ADM genes.

Conclusion

Our results demonstrate increased IFN-γ responses in skin of patients with AD and suggest involvement of multiple new apoptosis- and inflammation-related factors in the development of AD.

Le texte complet de cet article est disponible en PDF.

Key words : Cytokine, mRNA expression array, atopic eczema, inflammation, allergy

Abbreviations used : 7-AAD, AD, FAS, FN14, KORA, qRT-PCR, SNP, TNF-R, TRAIL, TWEAK


Plan


 Supported by Swiss National Science Foundation grants 32-132899 and 32-112306, the Christine Kühne Center for Allergy Research and Education (CK-CARE), Estonian Ministry of Education and Research targeted funds SF0180021s07 and SF0180043s07, and Estonian Science Foundation grants ESF8350 and ETF7437. A.R. was supported by fellowships from the SCIEX Programme NMS-CH and ESTBIOREG. S.W. is supported by a Heisenberg professorship of the DFG (WE2678/4-1).
 Disclosure of potential conflict of interest: M. Akdis receives research support from the Swiss National Foundation and the European Union. N. Novak has received research support from the German Research Council; has received lecture fees from Astellas and ALK-Abelló; and is on an advisory board for LEO Pharma. C. A. Akdis has received research support from Novartis, PREDICTA, the Swiss National Science Foundation, MeDALL, the Global Allergy and Asthma European Network, and the Christine Kühne Center for Allergy Research and Education and has consulted for Actellion, Aventis, Stallergenes, and Allergopharma. The rest of the authors declare that they have no relevant conflicts of interest.


© 2012  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 129 - N° 5

P. 1297-1306 - mai 2012 Retour au numéro
Article précédent Article précédent
  • Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections
  • Gabriela Senti, Reto Crameri, Daniela Kuster, Pål Johansen, Julia M. Martinez-Gomez, Nicole Graf, Martin Steiner, Ludwig A. Hothorn, Hans Grönlund, Christine Tivig, Anna Zaleska, Ozge Soyer, Marianne van Hage, Cezmi A. Akdis, Mübeccel Akdis, Horst Rose, Thomas M. Kündig
| Article suivant Article suivant
  • Chronic urticaria and autoimmunity: Associations found in a large population study
  • Ronit Confino-Cohen, Gabriel Chodick, Varda Shalev, Moshe Leshno, Oded Kimhi, Arnon Goldberg

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.